by Market Overview:
Plasmid DNA refers to small, circular DNA molecules in bacteria that are physically separated from chromosomal DNA and capable of autonomous replication. They are used to transfer desirable genes into host cells being used for gene and cell therapy. Plasmid DNA is manufactured from a plasmid vector containing the therapeutic gene sequence. During manufacturing, the plasmid vector replicates within bacterial or yeast host cells to produce copies of the therapeutic gene. The harvested plasmid DNA is then purified, analyzed and formulated for downstream applications. Plasmid DNA manufacturing holds advantages over traditional pharmaceutical manufacturing approaches as they allow large scale production of genetic material with relatively low costs. The ability to mass produce DNA for gene and cell therapy has made plasmid DNA an important tool in the biomanufacturing industry.
The Plasmid DNA manufacturing market is estimated to be valued at US$ 901.2 Bn or Mn in 2023 and is expected to exhibit a CAGR of 35% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends driving the plasmid DNA manufacturing market is the rapid growth in gene therapy development and commercialization. Since gene therapy relies on delivering functional genes into patient cells to replace mutated genes or restore normal gene function, there is an increasing demand for high quality plasmid DNA. Many pharmaceutical companies are actively investing in plasmid DNA manufacturers to support their gene therapy pipeline. Additionally, the expansion of cell therapy manufacturing using genetically modified cell lines is another factor fueling the need for large quantities of plasmid DNA. Rapid advancements in DNA synthesis technology allowing high throughput, scalable and precise plasmid production has increased the feasibility and reduced the costs of plasmid DNA manufacturing. This has further accelerated plasmid DNA adoption among biopharmaceutical manufacturers.
Porter’s Analysis
Threat of new entrants: The Plasmid DNA manufacturing market requires high capital investments, complex technology and strict regulatory compliance. These barriers lessen the threat of new entrants.
Bargaining power of buyers: Given the life-saving applications of plasmid DNA, the bargaining power of large pharmaceutical companies as buyers is high. However, the presence of many regional suppliers balances this power.
Bargaining power of suppliers:There are many suppliers of raw materials and equipment required for plasmid DNA manufacturing. This reduces their bargaining power in the market.
Threat of new substitutes: There are no cost-effective substitutes available for plasmid DNA currently. Hence, the threat of substitutes is low.
Competitive rivalry: The market has the presence of many international and domestic players. Players focus on technology advancements and strong R&D to gain competitive edge.
Key Takeaways
The Global Plasmid DNA Manufacturing Market Size is expected to witness high growth, exhibiting CAGR of 35% over the forecast period, due to increasing demand for gene and cell therapies.
Regional analysis
North America dominates the global Plasmid DNA manufacturing market currently. Asia Pacific is expected to witness highest growth rate over the forecast period owing to growing biologics industry and gene therapy clinical trials in China, Japan and India.
Key players
Key players operating in the Plasmid DNA manufacturing market include Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
